Skip to content

BBNX BBNX Total Revenue

Total Revenue at other companies

Insulet logo
InsuletPODD
$761.7M+33.9%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$247.22M+5.5%
Medtronic logo
MedtronicMDT
$9.81B+9.9%
AdaptHealth logo
AdaptHealthAHCO
$819.8M+5.4%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$376.71M+42.2%

Segments

By product

See full
Single Use Products$10.24M+144%
I Let$10.09M+4.8%

By geography

See full
Non Us$0

Other financials

Income statement

See full
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Reported directly by BBNX in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's total revenue?
BBNX (BBNX) reported total revenue of $27.63M in Q1 2026.
How has BBNX's total revenue changed year-over-year?
BBNX's total revenue increased by 56.6% year-over-year, from $17.64M to $27.63M.
What is the long-term trend for BBNX's total revenue?
Over 2 years (2023 to 2025), BBNX's total revenue has grown at a 189.1% compound annual growth rate (CAGR), from $12M to $100.25M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.